

CLAIMS AMENDMENT

1-38. (canceled)

39. (previously presented): A method for treating or ameliorating at least one disorder mediated by the CXCR4 receptor which method comprises administering to a subject in need of such treatment or amelioration an effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 1,1'-[1,4-(phenylenebis(methylene))]bis-1,4,8,11-tetraazacyclotetradecane.

40. (previously presented): The method of claim 39 wherein said disorder is arthritis.

41. (canceled)

42. (Currently amended): The method of claim 39 wherein said disorder is [[leukemia or]] lymphoma.

43-44. (canceled)

45. (previously presented): The method of claim 39 wherein said disorder is central nervous system developmental disease.

46. (previously presented): The method of claim 39 wherein said disorder is vasculature development disease of the gastrointestinal tract.

47. (previously presented): The method of claim 39 wherein said disorder is cardiogenesis developmental disease.

48. (previously presented): The method of claim 39 wherein said disorder is glioblastoma.

49. (New): The method of claim 39, wherein said disorder comprises basal leukocyte trafficking.

50. (New): The method of claim 39, wherein said disorder comprises extravasation and tissue infiltration of leukocytes in response to inciting antigens.